readthroughSign in
CompanyGMABGNMSFNasdaq, OTC1253 Copenhagen K, G7

Genmab A/S

Genmab develops antibody-based therapeutics including bispecific antibodies, antibody-drug conjugates, and immune-modulating antibodies for cancer and serious diseases.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 10Latest story

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026